Organization | GU Research Network, LLC

GU Research Network, LLC Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2012

NCT01751451

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

GU Research Network, LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

abiraterone (zytiga) (2 trials)

methylprednisolone (medrol) (1 trial)

Drugs in Phase 2 Trials (6)

ags-003 (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

degarelix acetate (firmagon) (1 trial)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 8